Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex in Social Anxiety Disorder
NCT05649059Phase 4Recruiting
- Sponsor
- Massachusetts Institute of Technology
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cannabidiol in Social Anxiety Disorder (SAD), sponsored by Massachusetts Institute of Technology. Started Jul 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT05649059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649059.